» Articles » PMID: 2024957

Anti-Toxoplasma Effects of Dapsone Alone and Combined with Pyrimethamine

Overview
Specialty Pharmacology
Date 1991 Feb 1
PMID 2024957
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The efficacy of dapsone alone or combined with pyrimethamine against Toxoplasma gondii was investigated experimentally. For in vitro studies, a sensitive immunoassay was used for assessment of Toxoplasma growth in tissue cultures; dapsone was found to have a significant inhibitory effect at a concentration of 0.5 micrograms/ml in the cultures, and the 50% inhibitory concentration was estimated to be 0.55 micrograms/ml. When pyrimethamine and dapsone were combined, an important synergistic effect which was associated with morphological alterations of the parasites was observed. In vivo studies were performed in a murine model of acute toxoplasmosis in which a tissue culture method was used to estimate the parasite burden in the blood, lungs, and brains of infected mice. Dapsone alone, which was administered at 100 mg/kg/day for 10 days from day 1 after infection, was unable to prevent parasite dissemination and only delayed the time to death of treated mice compared with the time of death of untreated controls. When dapsone and pyrimethamine (18.5 mg/kg/day) were administered in combination from day 4 after infection, parasites were cleared from blood and organs within 6 days, but relapses were observed 15 days after the cessation of therapy. When treatment was started at day 1 after infection, 100% of mice survived and relapses were not observed, suggesting a good efficacy of this combination for preventive therapy.

Citing Articles

Synthesis, In Vitro, and In Silico Analysis of the Antioxidative Activity of Dapsone Imine Derivatives.

Guzman-Avila R, Avelar M, Marquez E, Rivera-Leyva J, Mora J, Flores-Morales V Molecules. 2021; 26(19).

PMID: 34641292 PMC: 8510498. DOI: 10.3390/molecules26195747.


Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Dunay I, Gajurel K, Dhakal R, Liesenfeld O, Montoya J Clin Microbiol Rev. 2018; 31(4).

PMID: 30209035 PMC: 6148195. DOI: 10.1128/CMR.00057-17.


In Vitro and in Vivo Effects of Nitrofurantoin on Experimental Toxoplasmosis.

Yeo S, Jin C, Kim S, Park H Korean J Parasitol. 2016; 54(2):155-61.

PMID: 27180573 PMC: 4870977. DOI: 10.3347/kjp.2016.54.2.155.


Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Neville A, Zach S, Wang X, Larson J, Judge A, Davis L Antimicrob Agents Chemother. 2015; 59(12):7161-9.

PMID: 26392504 PMC: 4649158. DOI: 10.1128/AAC.02009-15.


Opportunistic infections in HIV-infected patients.

Shafran S Can J Infect Dis. 2012; 3(2):82-7.

PMID: 22529738 PMC: 3328018. DOI: 10.1155/1992/413713.


References
1.
Oshima S, Inami Y, Tanaka H . Prophylactic effect of 2-sulfamoyl-4,4'-diaminodiphenylsulfone (SDDS) on experimental infection with Toxoplasma in pigs. Am J Trop Med Hyg. 1970; 19(3):422-6. DOI: 10.4269/ajtmh.1970.19.422. View

2.
SUMMERS W . The effects of oral administration of aureomycin, sulfathiazole, sulfamerazine and 4,4'-diamino diphenyl sulfone on toxoplasmosis in mice. Am J Trop Med Hyg. 1949; 29(6):889-93. DOI: 10.4269/ajtmh.1949.s1-29.889. View

3.
Hughes W, Smith B . Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1984; 26(4):436-40. PMC: 179940. DOI: 10.1128/AAC.26.4.436. View

4.
Zuidema J, Merkus F . Clinical pharmacokinetics of dapsone. Clin Pharmacokinet. 1986; 11(4):299-315. DOI: 10.2165/00003088-198611040-00003. View

5.
Pieters F, Zuidema J . The pharmacokinetics of dapsone after oral administration to healthy volunteers. Br J Clin Pharmacol. 1986; 22(4):491-4. PMC: 1401154. DOI: 10.1111/j.1365-2125.1986.tb02924.x. View